User:FrancoThomas87/sandbox

Sphere Fluidics Limited
Sphere Fluidics is an England-based Life Sciences Research and Development company specializing in biopharmaceutical discovery and development, cell therapy engineering, analysis and isolation. Sphere Fluidics has been named one of the UK's top 50 disruptive SMEs by Real Business in 2015.

History
Sphere Fluidics Limited was originally established in 2010, by two chemistry professors of Cambridge University, namely, Professor Chris Abell and Professor Wilhelm Huck along with Frank F.Craig, an entrepreneur, and Dr.Maher Khaled, a Cambridge University Enterprise.

In 2013, Sphere Fluidics spun out of Cambridge university to a new research facility in Babraham Research Campus. In 2013, Sphere Fluidics won an award for academic spin-outs at the ACES awards.

Overview
In the earlier stages, Sphere Fluidics marketed in the biopharmaceuticals industry, largely. Currently, they operate in anti-microbial screening, synthetic biology, and genome editing of single cells areas, too.

In 2015, Sphere Fluidics was among the top 20 Intellectual Property League Table Entrants. As of 2017, Sphere Fluidics has 36 granted patents and 16 trademarks.

In January 2017, Sphere Fluidics launched an e-commerce platform which had, microfluidic products, research instrument accessories, and microfluidic biochips, on its product line.

In July 2017, Sphere Fluidics won “Best Investment in Life Sciences” Award, in the event held by UK Business Angels Association.

In August 2017, a new lab and facility from Sphere Fluidics was opened in Monmouth Junction, New Jersey.

Funding
Sphere Fluidics has raised £11 million as of 2017, from investors namely, 24 Haymarket, Amadeus Capital Partners, Greenwood Way Capital, University of Cambridge Enterprise, University of Cambridge, Parkwalk Advisors, Providence Investment Company, London Business Angels , Envestors, Angels5K, Cambridge Angels, Q-Ventures and a Japanese corporate investor.

Cyto-Mine Technology
Cyto-Mine Technology is one of the patented products of Sphere Fluidics.

Cyto-Mine technology is the integrated device that is able to automatically perform single cell analysis, sorting, imaging and dispensing into individual wells of microtitre plates in a single compact system. Based on the research made by Professors Chris Abell and Wilhelm Huck, this biochip system can automatically process millions to billions of miniaturised tests in tiny picodroplets.

According to the scientists of Sphere Fluidics, Cyto-Mine can perform millions of single-cell assays daily, offering up to a 100-fold improvement over conventional techniques, at lower capital and operational cost.